{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:20:04Z","timestamp":1784193604335,"version":"3.55.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.antiviral.2008.04.002","type":"journal-article","created":{"date-parts":[[2008,5,14]],"date-time":"2008-05-14T08:32:27Z","timestamp":1210753947000},"page":"179-187","source":"Crossref","is-referenced-by-count":60,"title":["A case for developing antiviral drugs against polio"],"prefix":"10.1016","volume":"79","author":[{"given":"Marc S.","family":"Collett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Modlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2008.04.002_bib1","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1128\/JVI.70.6.3536-3544.1996","article-title":"Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins","volume":"70","author":"Aberham","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0166-3542(87)90085-4","article-title":"Studies of rhinovirus resistant to an antiviral chalcone","volume":"8","author":"Ahmad","year":"1987","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2008.04.002_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1146\/annurev.mi.41.100187.001101","article-title":"The attenuation of poliovirus neurovirulence","volume":"41","author":"Almond","year":"1987","journal-title":"Ann. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/135965350701200S04.1","article-title":"Influenza virus susceptibility and resistance to oseltamivir","volume":"12","author":"Aoki","year":"2007","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.antiviral.2008.04.002_bib5","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1086\/520546","article-title":"Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants","volume":"196","author":"Asturias","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2008.04.002_bib6","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/JB.91.3.1289-1294.1966","article-title":"Inhibition of enterovirus cytopathic effects by 2-(alpha-hydroxybenzyl)-benzimidazole","volume":"91","author":"Bablanian","year":"1966","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib7","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1073\/pnas.49.6.843","article-title":"Poliovirus-induced RNA polymerase and the effects of virus-specific inhibitors on its production","volume":"49","author":"Baltimore","year":"1963","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2008.04.002_bib8","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/AAC.48.5.1766-1772.2004","article-title":"In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity","volume":"48","author":"Barnard","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2008.04.002_bib9","first-page":"529","article-title":"The effect of guanidine: (1) On experimental poliomyelitis induced by oral administration of virus to cynomolgus monkeys; (2). On naturally occurring enteroviruses of cynomolgus monkeys","volume":"19","author":"Barrbera-Oro","year":"1961","journal-title":"Tex. Rep. Biol. Med."},{"key":"10.1016\/j.antiviral.2008.04.002_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00431-002-0929-5","article-title":"Severe Coxsackie virus B infection in preterm newborns treated with pleconaril","volume":"161","author":"Bauer","year":"2002","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.antiviral.2008.04.002_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1128\/AAC.49.2.619-626.2005","article-title":"Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor","volume":"49","author":"Binford","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2008.04.002_bib12","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1128\/AAC.00905-07","article-title":"In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease","volume":"51","author":"Binford","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2008.04.002_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4049\/jimmunol.69.4.441","article-title":"The influence of chemicals on the propagation of poliomyelitis virus in tissue culture","volume":"69","author":"Brown","year":"1952","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib14","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3181\/00379727-83-20374","article-title":"Effect of benzimidazole on experimental poliomyelitis in mice and monkeys","volume":"83","author":"Brown","year":"1953","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.antiviral.2008.04.002_bib15","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.bmcl.2005.02.054","article-title":"2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder","volume":"15","author":"Brown","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2008.04.002_bib16","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1128\/AAC.41.6.1220","article-title":"SCH 48973 a potent, broad-spectrum, antienterovirus compound","volume":"41","author":"Buontempo","year":"1997","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.antiviral.2008.04.002_bib17","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1099\/vir.0.18974-0","article-title":"Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis","volume":"84","author":"Buttinelli","year":"2003","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0163-7258(94)90040-X","article-title":"Picornavirus inhibitors","volume":"64","author":"Carrasco","year":"1994","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2008.04.002_bib19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3181\/00379727-85-20799","article-title":"Antiviral action of a mold filtrate on experimental poliomyelitis in cynomolgus monkeys","volume":"85","author":"Cochran","year":"1954","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.antiviral.2008.04.002_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0166-3542(95)00979-5","article-title":"Antipicornavirus activity of SCH 47802 and analogs: in vitro and in vivo studies","volume":"32","author":"Cox","year":"1996","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2008.04.002_bib21","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1128\/JVI.78.7.3378-3386.2004","article-title":"The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein","volume":"78","author":"Crotty","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib22","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1056\/NEJMoa054960","article-title":"Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba","volume":"356","year":"2007","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.antiviral.2008.04.002_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1086\/508427","article-title":"Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico","volume":"195","author":"Dayan","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2008.04.002_bib24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3201\/eid1404.070439","article-title":"Comparative activity of a selected series of anti-picornavirus compounds against poliovirus replication in vitro","volume":"14","author":"De Palma","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2008.04.002_bib25","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/aje\/kwi206","article-title":"A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future","volume":"162","author":"Duintjer Tebbens","year":"2005","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0166-3542(85)80009-7","article-title":"Antiviral agents against picornaviruses","volume":"1","author":"Eggers","year":"1985","journal-title":"Antiviral Res. Suppl."},{"key":"10.1016\/j.antiviral.2008.04.002_bib27","first-page":"58","article-title":"Antiviral drugs\u2014a short history of their discovery and development","volume":"31","author":"Field","year":"2004","journal-title":"Microbiol. Today"},{"key":"10.1016\/j.antiviral.2008.04.002_bib28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1128\/AAC.30.1.110","article-title":"Prevention of rhinovirus and poliovirus uncoating by WIN 51711 a new antiviral drug","volume":"30","author":"Fox","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2008.04.002_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3181\/00379727-85-20793","article-title":"Effect of fluoroacetate upon poliomyelitis in monkeys","volume":"85","author":"Francis","year":"1954","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.antiviral.2008.04.002_bib30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1101\/gad.1505307","article-title":"Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance","volume":"21","author":"Geller","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.antiviral.2008.04.002_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.antiviral.2007.10.006","article-title":"NIAID resources for developing new therapies for severe viral infections","volume":"78","author":"Greenstone","year":"2007","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2008.04.002_bib32","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/314758","article-title":"Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants","volume":"179","author":"Groarke","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2008.04.002_bib33","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1128\/AAC.39.2.290","article-title":"Intranasal pirodavir (R77 975) treatment of rhinovirus colds","volume":"39","author":"Hayden","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2008.04.002_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/135965350200700107","article-title":"Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials","volume":"7","author":"Hayden","year":"2002","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.antiviral.2008.04.002_bib35","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1086\/375069","article-title":"Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials","volume":"36","author":"Hayden","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2008.04.002_bib36","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1128\/AAC.47.12.3907-3916.2003","article-title":"Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers","volume":"47","author":"Hayden","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2008.04.002_bib37","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1128\/JVI.69.7.4189-4197.1995","article-title":"The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus","volume":"69","author":"Heinz","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib38","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1128\/JVI.63.6.2476-2485.1989","article-title":"Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound","volume":"63","author":"Heinz","year":"1989","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib39","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0042-6822(92)90178-R","article-title":"Involvement of membrane traffic in the replication of poliovirus genomes: effects of brefeldin A","volume":"191","author":"Irurzun","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2008.04.002_bib40","series-title":"Modern Approaches to Vaccines","first-page":"357","article-title":"Evolution of the oral poliovaccine strains in humans occurs by both mutation and intramolecular recombination","author":"Kew","year":"1984"},{"key":"10.1016\/j.antiviral.2008.04.002_bib41","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1128\/JCM.36.10.2893-2899.1998","article-title":"Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient","volume":"36","author":"Kew","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib42","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1126\/science.1068284","article-title":"Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus","volume":"296","author":"Kew","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2008.04.002_bib43","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib44","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1086\/379791","article-title":"Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis","volume":"188","author":"Khetsuriani","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2008.04.002_bib45","first-page":"495","article-title":"Influence of pyrimidine analogs and related compounds on the propagation of poliomyelitis virus in tissue culture","volume":"119","author":"Knox","year":"1957","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.antiviral.2008.04.002_bib46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.antiviral.2005.08.003","article-title":"Basis for natural phenotypic resistance of human rhinoviruses to pleconaril","volume":"68","author":"Ledford","year":"2005","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2008.04.002_bib47","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S0140-6736(04)16150-3","article-title":"Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man","volume":"363","author":"MacLennan","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2008.04.002_bib48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.biologicals.2006.02.005","article-title":"Vaccine-derived poliovirus from long term excretors and the end game of polio eradication","volume":"34","author":"Mart\u00edn","year":"2006","journal-title":"Biologicals."},{"key":"10.1016\/j.antiviral.2008.04.002_bib49","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1128\/JVI.74.7.3001-3010.2000","article-title":"Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion","volume":"74","author":"Mart\u00edn","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib50","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1128\/JVI.66.4.1985-1994.1992","article-title":"Inhibition of poliovirus RNA synthesis by brefeldin A","volume":"66","author":"Maynell","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib51","first-page":"109","article-title":"Discovery and development of antipicornaviral agents","volume":"88","author":"McKinlay","year":"1993","journal-title":"Scand. J. Infect. Dis. Suppl."},{"key":"10.1016\/j.antiviral.2008.04.002_bib52","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1128\/AAC.29.1.30","article-title":"Oral efficacy of WIN 51711 in mice infected with human poliovirus","volume":"29","author":"McKinlay","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2008.04.002_bib53","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev.mi.46.100192.003223","article-title":"Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment","volume":"46","author":"McKinlay","year":"1992","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib54","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1099\/0022-1317-65-2-377","article-title":"Action of human lymphoblastoid interferon on HeLa cells infected with RNA-containing animal viruses","volume":"65","author":"Mu\u00f1oz","year":"1984","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib55","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1128\/JVI.75.2.1039-1043.2001","article-title":"A single amino acid substitution in the ICP27 protein of herpes simplex virus type 1 is responsible for its resistance to leptomycin B","volume":"75","author":"Murata","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib56","unstructured":"NRC, 2006. http:\/\/books.nap.edu\/catalog\/11599.html#toc."},{"key":"10.1016\/j.antiviral.2008.04.002_bib57","unstructured":"Oberste, S., Pevear, D., Pallansch, M., Collett, M.S., in preparation. Anti-poliovirus spectrum of activity of capsid inhibitor V-073."},{"key":"10.1016\/j.antiviral.2008.04.002_bib58","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1086\/518939","article-title":"John F. Enders lecture 2006: antivirals for influenza","volume":"196","author":"Ong","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2008.04.002_bib59","unstructured":"Pallansch-Cokonis, M., Ptak, R., 2008. Personal communication."},{"key":"10.1016\/j.antiviral.2008.04.002_bib60","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.antiviral.2006.03.011","article-title":"Rhinovirus chemotherapy","volume":"71","author":"Patick","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2008.04.002_bib61","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1128\/AAC.43.10.2444","article-title":"In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease","volume":"43","author":"Patick","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2008.04.002_bib62","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/AAC.49.6.2267-2275.2005","article-title":"In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease","volume":"49","author":"Patick","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2008.04.002_bib63","unstructured":"Polio Eradication, 2008a. http:\/\/www.polioeradication.org\/."},{"key":"10.1016\/j.antiviral.2008.04.002_bib64","unstructured":"Polio Eradication, 2008b. www.polioeradication.org\/content\/general\/AnnualExpenditures&RequirementsJan08.pdf."},{"key":"10.1016\/j.antiviral.2008.04.002_bib65","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.134.3478.558","article-title":"Antiviral effect of guanidine","volume":"134","author":"Rightsel","year":"1961","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2008.04.002_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(97)00068-5","article-title":"Treatment of human enterovirus infections","volume":"38","author":"Rotbart","year":"1998","journal-title":"Anitviral Res."},{"key":"10.1016\/j.antiviral.2008.04.002_bib67","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/315176","article-title":"Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection","volume":"181","author":"Schiff","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2008.04.002_bib68","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1128\/JVI.74.9.4146-4154.2000","article-title":"Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives","volume":"74","author":"Shimizu","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2008.04.002_bib69","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/clinids\/14.2.568","article-title":"Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease","volume":"14","author":"Strebel","year":"1992","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2008.04.002_bib70","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.antiviral.2008.01.002","article-title":"R 75761, a lead compound for development of antiviral drugs for late stage poliomyelitis eradication strategies and beyond","volume":"78","author":"Thys","year":"2008","journal-title":"Antiviral. Res."},{"key":"10.1016\/j.antiviral.2008.04.002_bib71","first-page":"286","article-title":"Polio-like myelitis due to Coxsackie-Virus B3: course under treatment with pleconaril","volume":"215","author":"Utzig","year":"2003","journal-title":"Klin. Padiatr."},{"key":"10.1016\/j.antiviral.2008.04.002_bib72","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1021\/jm0202876","article-title":"An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus","volume":"46","author":"Watson","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2008.04.002_bib73","unstructured":"Weekly Epidemiological Record, 2006. Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication 81, 465\u2013468."},{"key":"10.1016\/j.antiviral.2008.04.002_bib74","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1021\/jm00178a004","article-title":"Synthesis of syn and anti isomers of 6-[[(hydroxyimino) phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1 H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication","volume":"23","author":"Wikel","year":"1980","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2008.04.002_bib75","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1098\/rspb.2003.2664","article-title":"Immune responses and the emergence of drug-resistant virus strains in vivo","volume":"271","author":"Wodarz","year":"2004","journal-title":"Proc. Biol. Sci."},{"key":"10.1016\/j.antiviral.2008.04.002_bib76","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1128\/AAC.34.6.963","article-title":"Pathogenicity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410","volume":"34","author":"Yasin","year":"1990","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354208002854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354208002854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T09:51:19Z","timestamp":1684403479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354208002854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0166354208002854"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2008.04.002","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}